Clinical Knowledge Summary: Atherosclerotic Cardiovascular Disease Prevention (Longevity Medicine)

 

1. Scope

What is covered:

– Risk stratification and biomarker assessment (traditional risk scores, apoB, Lp(a), coronary artery calcium/CCTA).

– Lipid-lowering therapy (statins, ezetimibe, bempedoic acid, PCSK9 monoclonal antibodies, inclisiran), blood pressure control, glucose-lowering agents with cardiovascular benefit (GLP-1 receptor agonists, SGLT2 inhibitors), anti-inflammatory therapy (colchicine), icosapent ethyl, aspirin, and lifestyle.

– Emerging and off-label interventions relevant to longevity practice (senolytics/senomorphics, emerging Lp(a)-lowering agents), explicitly flagged by evidence level.

What is not covered: Acute coronary syndrome management, revascularisation, secondary-prevention antithrombotic regimens in detail, heart failure management, and paediatric familial hypercholesterolaemia protocols.

Positioning: This summary is adjunctive to — not a replacement for — NHS primary and secondary care. It assumes the longevity clinician works alongside the patient’s GP and relevant specialists, with clear communication and shared records.

 

2. Background and pathophysiology

– ASCVD is driven by the lifelong retention of apolipoprotein B (apoB)-containing lipoproteins (LDL, VLDL, remnants, IDL, Lp(a)) within the arterial intima, triggering a maladaptive inflammatory response, plaque formation, and eventual rupture/erosion. apoB is the causal particle; LDL-C is a cholesterol-mass surrogate that can under- or over-estimate particle burden.[1][2][3]

– The cumulative LDL/apoB exposure model (area under the curve of lifetime exposure) explains why earlier and sustained lowering yields disproportionately large benefit — Mendelian randomisation and long-duration trials show a steeper slope of event reduction with longer treatment.[4]

– Residual inflammatory risk persists despite optimal lipid lowering; hs-CRP and IL-6 predict events independent of residual cholesterol, providing the rationale for anti-inflammatory therapy (colchicine, IL-1β inhibition).[5][6]

– Vascular ageing mechanisms relevant to longevity practice include endothelial and vascular smooth-muscle cellular senescence and the senescence-associated secretory phenotype (SASP), which promote inflammaging and plaque instability.[7]

Preclinical mechanistic evidence only (not for routine clinical inference):

– Senolytics (dasatinib + quercetin, fisetin) reduce senescent-cell burden, plaque area, intimal calcification and necrotic-core expansion, and improve vascular relaxation in aged and ApoE−/− mice.[7][8]

– Senomorphics (rapamycin, metformin, resveratrol) suppress SASP cytokine release in cell lines and animal models; precise human vascular mechanism is unknown.[7][8]

– No robust human ASCVD-outcome data exist for any senolytic or senomorphic; these remain hypothesis-generating.[7]

 

3. Evidence base and grading

Evidence certainty below uses a GRADE-style framework (High/Moderate/Low/Very low). Strength of recommendation is stated per outcome.

Statins — reduction in major vascular events

– Evidence statement: High-certainty evidence from the Cholesterol Treatment Trialists (CTT) individual-patient meta-analyses and dozens of RCTs; each ~1 mmol/L LDL-C reduction lowers major vascular events by ~21–22%, with a further 15% reduction for more- vs less-intensive regimens (n=39,612).[1]

– Limitations: minimal; consistent across baseline LDL-C, age, sex, diabetes. Imprecision low. Publication bias low.

– Strong recommendation (guideline-based, on-label).[9][1]

Ezetimibe added to statin — MI/stroke reduction

– Moderate-to-high certainty (network meta-analysis, 14 trials, n=83,660; IMPROVE-IT). Adds ~6% relative MI reduction; benefit concentrated in high/very-high-risk patients; no mortality benefit.[10][11]

– Strong/Conditional recommendation depending on risk (on-label).[9][10]

PCSK9 monoclonal antibodies (evolocumab, alirocumab) — MACE reduction

– High certainty (FOURIER, ODYSSEY OUTCOMES; meta-analyses). ~15% MACE RRR over ~2.2–2.8 y; alirocumab reduced all-cause mortality in ODYSSEY.[10][1][12][13]

– Strong recommendation in very-high-risk/secondary prevention not at goal (on-label).[1]

Bempedoic acid — MI/revascularisation in statin-intolerant patients

– Moderate-to-high certainty (CLEAR Outcomes). ~20% LDL-C reduction, reduces MI and coronary revascularisation in statin-intolerant patients.[1]

– Conditional/Strong recommendation in statin intolerance (on-label).[1][14]

Inclisiran (siRNA) — LDL-C lowering; outcomes pending

– Moderate certainty for LDL-C (~50% reduction); Low/Very low for hard outcomes — cardiovascular outcome trials ongoing.[1][12]

– Conditional recommendation for LDL-C lowering; hard-outcome benefit only inferred (on-label for LDL-C).[1][14]

Icosapent ethyl (4 g/day) — MACE in treated hypertriglyceridaemia

– Moderate certainty (REDUCE-IT, n=8,179; 25% RRR primary endpoint). Mineral-oil comparator and increased atrial fibrillation temper certainty.[15][16]

– Conditional recommendation in statin-treated patients with TG 1.5–5.6 mmol/L and ASCVD/diabetes (on-label).[15]

Colchicine 0.5 mg/day — secondary prevention MACE

– Moderate certainty (LoDoCo2, COLCOT; meta-analysis ~25–31% MACE RRR) but neutral CLEAR SYNERGY introduces inconsistency; all-cause mortality neutral.[17][18]

– Conditional recommendation in chronic coronary disease/post-MI (on-label for CV risk reduction in some regions).[6][19]

Blood pressure lowering to intensive targets

– High certainty (SPRINT, ESPRIT, STEP, BPLTTC/network meta-analyses); each 10 mmHg SBP reduction lowers major CVD events; intensive SBP <120 mmHg reduces events and mortality in high-risk adults.[20][21][22][23]

– Strong recommendation (guideline-based).[20]

GLP-1 receptor agonists / SGLT2 inhibitors — MACE

– High certainty in type 2 diabetes (multiple CVOTs, meta-analyses; ~12–21% MACE RRR). Semaglutide reduces MACE in obesity without diabetes (SELECT) — on-label.[24][25][26][14]

– Strong recommendation in diabetes/established ASCVD; Conditional in obesity without diabetes.[24][14]

Aspirin — primary prevention

– Moderate certainty (USPSTF systematic review, 13 RCTs): small MI/stroke reduction offset by bleeding; no mortality benefit.[27][28]

– Recommend against routine use; individualised only in selected 40–59-year-olds at ≥10% 10-year risk and low bleeding risk (conditional).[27]

Mediterranean/low-fat dietary programmes

– Moderate certainty (PREDIMED RCT; network meta-analysis, 40 RCTs, n=35,548): Mediterranean programme reduces all-cause and CV mortality, stroke, and MI.[29][30][31][32]

– Strong recommendation (guideline-based lifestyle).[29][30]

Senolytics / senomorphics for ASCVD

– Very low certainty — preclinical/mechanistic only; no human ASCVD-outcome RCTs.[7][8]

– Only in research.

Emerging Lp(a)-lowering therapies (pelacarsen, olpasiran, muvalaplin)

– Very low certainty for outcomes — potent Lp(a) lowering (up to ~80%) demonstrated; outcome trials ongoing.[33][34]

– Only in research (for outcome benefit).

 

4. Patient selection and indications

Who may benefit (inclusion):

– Adults ~30–79 years without established ASCVD, for risk-stratified primary prevention; treat earlier and more aggressively where cumulative exposure is high.[9][35]

– Middle-aged adults with cardiometabolic risk (raised apoB/LDL-C, hypertension, dysglycaemia, central adiposity, metabolic syndrome) — highest yield group.[1][36]

– Elevated Lp(a) (≥50 mg/dL / ≥125 nmol/L; ~20% of population) — multiplicative lifetime risk; intensify all modifiable factors early.[9][37]

– Discordantly elevated apoB despite at-goal LDL-C — identifies residual particle-burden risk, especially with TG ≥1.7 mmol/L or diabetes.[1][38]

– Subclinical atherosclerosis on CAC or CCTA (CAC ≥100 AU, or non-calcified plaque) — reclassifies to high risk and favours statin initiation.[35][39][40]

– Established ASCVD or diabetes — secondary prevention / high-intensity strategies (usually via conventional care).[1][24]

Clinical scenario nuances:

– Older adults with frailty/multimorbidity: absolute benefit of LDL and BP lowering persists, but weigh polypharmacy, falls, cognition, life expectancy, and patient goals; geroscience-framed individualisation.[8][41]

– Athletic/low-risk individuals seeking “optimisation”: favour lifestyle and biomarker monitoring; avoid low-yield pharmacotherapy where 10-year risk is low and CAC = 0 (though CAC = 0 gives false reassurance in smokers, diabetics, strong family history, high Lp(a)).[10][39]

Exclusion / caution groups:

– Pregnancy/lactation (statins, PCSK9i, bempedoic acid, icosapent ethyl not appropriate).[1]

– Active or decompensated liver disease (statins).[1]

– Significant renal/hepatic impairment or concomitant strong CYP3A4/P-gp inhibitors (colchicine risk).[17]

– High bleeding risk (aspirin).[27][42]

Regulatory/ethical status:

– On-label, guideline-based: statins, ezetimibe, bempedoic acid, PCSK9 mAbs, inclisiran (LDL-C), icosapent ethyl, antihypertensives, GLP-1 RA/SGLT2i (per indication), colchicine (region-dependent).

– Off-label / adjunctive with informed consent: apoB- or Lp(a)-guided intensification beyond LDL-C thresholds; colchicine where not locally licensed; GLP-1 RA/SGLT2i for CV risk in non-diabetic non-obese patients.

– Only in research / within trial frameworks: senolytics, senomorphics (e.g. rapamycin, metformin as anti-ageing), and specific Lp(a)-lowering agents for outcome benefit.[7][8][34]

 

5. Assessment and baseline work-up

History and examination: personal/family ASCVD history (premature CAD), smoking, diet, activity, alcohol; cardiometabolic comorbidity; medication and supplement review; bleeding risk; frailty assessment in older adults; blood pressure (standardised, ideally with home/ambulatory readings).[20][43]

Risk scoring:

– UK practice: QRISK3 (calibrated to the UK population) for 10-year risk.[44][45]

– ESC regions: SCORE2 / SCORE2-OP.[46]

– The 2026 ACC/AHA guideline uses PREVENT equations (10- and 30-year risk), which estimate ~40–50% lower 10-year risk than the older Pooled Cohort Equations.[9][47]

Baseline investigations:

– Fasting/non-fasting lipid profile including calculated LDL-C (Martin/Hopkins method preferred), non-HDL-C, and apoB (standardised, fasting-independent).[1][9]

– Lp(a) once in a lifetime for all adults (genetically determined).[9][37]

– HbA1c/fasting glucose, renal function (eGFR), liver function, TSH, full blood count; urate if bempedoic acid considered.[1]

– hs-CRP where residual inflammatory risk assessment or colchicine is contemplated.[5][6]

– CAC score for intermediate/borderline-risk patients where the treatment decision is uncertain (CAC 0 may defer, CAC ≥100 favours therapy). CCTA provides plaque burden/composition and modestly improves prediction beyond risk factors + CAC, but is not yet a guideline-mandated routine screening tool.[35][39][40][45][48]

Risk stratification for benefit vs harm:

– Benefit: greatest at higher absolute risk, higher apoB/LDL-C, higher Lp(a), and demonstrable subclinical atherosclerosis.[10][4][39]

– Harm: statin-associated muscle symptoms (~10% real-world intolerance), small new-onset diabetes risk, bleeding (aspirin), colchicine GI/interaction risk.[17][27][1]

Baseline documentation: risk score and category; apoB, LDL-C, non-HDL-C, Lp(a), hs-CRP; BP; CAC/CCTA findings; frailty status; and shared-decision-making record. These anchor meaningful follow-up.

 

6. Dosing regimens and practical implementation

Regimens supported by robust human outcome data:

Intervention	Typical regimen	LDL-C / effect	Evidence tier	Refs
High-intensity statin	Atorvastatin 20–80 mg OD or rosuvastatin 10–40 mg OD	≥50% LDL-C reduction	High (CTT)	[46]
Moderate-intensity statin	Atorvastatin 10–20 mg / rosuvastatin 5–10 mg / simvastatin 20–40 mg	30–49% LDL-C reduction	High	[9], [46]
Ezetimibe	10 mg OD (add-on or monotherapy if statin-intolerant)	~18–24% additional	Mod–High	[1], [10]
Bempedoic acid	180 mg OD (± ezetimibe)	~20%	Mod–High	[15], [46]
Evolocumab	140 mg SC every 2 weeks or 420 mg monthly	~55–60%	High	[15], [17]
Alirocumab	75–150 mg SC every 2 weeks	~45–60%	High	[15], [17]
Inclisiran	284 mg SC at day 0, 3 months, then 6-monthly	~50% (outcomes pending)	Mod (LDL)	[15], [46]
Icosapent ethyl	2 g twice daily (4 g/day)	25% MACE RRR	Moderate	[29]
Colchicine	0.5 mg OD	25–31% MACE RRR	Moderate	[1], [20]
Antihypertensives	Titrate to SBP <130 mmHg (consider <120 in high-risk)	10 mmHg → major event reduction	High	[2], [3]

[10][1][15][17][20][11][12][14][19][23][36]

Titration / strategy:

– Lipid lowering: start statin at intensity matched to risk; recheck lipids/apoB at ~8–12 weeks; add ezetimibe, then a PCSK9 mAb (the 2026 guideline no longer mandates ezetimibe before a PCSK9 mAb) to reach goals. “Lower is better” down to very low LDL-C is supported, with no de-escalation signal at LDL-C to a median ~30 mg/dL over 8 years.[1]

– Targets (very-high-risk secondary prevention): LDL-C <1.4 mmol/L and ≥50% reduction; consider apoB <65 mg/dL and non-HDL-C <2.2 mmol/L. Primary-prevention targets are risk-tiered.[1][35]

Non-pharmacological protocols (robust data):

– Mediterranean dietary pattern (extra-virgin olive oil as main fat, tree nuts, legumes, fish, minimally processed plant foods; low saturated fat) — PREDIMED-style; ~29% MACE reduction in primary prevention.[29][31][49]

– Physical activity: ≥150 min/week moderate activity (guideline-standard); improves BP, LDL-C, adiposity.[43][50]

– Smoking cessation, weight management, alcohol reduction — foundational, particularly with elevated Lp(a) (Life’s Essential 8 associated with 67% lower ASCVD risk in high-Lp(a) individuals).[9]

Regimens extrapolated from early-phase/preclinical data — use only within research/registry frameworks:

– Senolytics (dasatinib + quercetin intermittent “hit-and-run” dosing; fisetin) — no validated human ASCVD dosing; no robust human outcome data.[7][8]

– Senomorphics (rapamycin, metformin for anti-ageing) — mechanistic plausibility only for vascular ageing; not established for ASCVD prevention.[7][8]

– Emerging Lp(a) agents (pelacarsen, olpasiran) — investigational; dosing confined to trials.[33][34]

 

7. Monitoring, safety and follow-up

Monitoring plan:

– Lipids/apoB at baseline, ~8–12 weeks after any change, then 6–12 monthly once stable.[1]

– LFTs before and after starting statin + ezetimibe; CK only if muscle symptoms.[1]

– Bempedoic acid: monitor urate (hyperuricaemia/gout), and note benign BUN/creatinine rise.[14][1]

– Colchicine: renal/hepatic function; review interacting drugs.[17]

– BP: home/ambulatory monitoring; renal function and electrolytes after antihypertensive changes.[20]

– hs-CRP where tracking inflammatory risk/colchicine response.[5][6]

Suggested intervals: short-term (6–12 weeks) after initiation/titration; medium-term (6 months); long-term (annual) once stable, with periodic reassessment of global risk and adherence.

Adverse effects:

– Statins: dose-related myalgia (normal CK) common; ~10% real-world intolerance; myopathy/myositis rare; rhabdomyolysis and immune-mediated necrotising myopathy very rare; small increase in new-onset diabetes in predisposed patients (BMI ≥30, fasting glucose ≥100 mg/dL, HbA1c 6.0–6.4%) — not a reason to stop; transaminase elevation rare; cognitive complaints rare/reversible and not seen in RCTs.[1][9]

– Ezetimibe: well tolerated; avoid in moderate/severe hepatic impairment.[1]

– PCSK9 mAbs / inclisiran: injection-site reactions; rare hypersensitivity/angio-oedema; some evolocumab syringe covers contain latex.[1]

– Bempedoic acid: hyperuricaemia, gout; tendon rupture risk noted in labelling.[14][1]

– Icosapent ethyl: increased atrial fibrillation/flutter (3.1% vs 2.1%); trend to increased serious bleeding.[15]

– Colchicine: GI intolerance (~10% withdrawal in run-in); small pneumonia signal; myopathy risk rises with renal/hepatic impairment or strong CYP3A4/P-gp inhibitors.[17]

– Aspirin: GI and intracranial bleeding (major bleeding HR ~1.43); NNT ~241 vs NNH ~880 for intracranial haemorrhage.[28][42]

Actions for abnormal findings: for SAMS, de-challenge/re-challenge, dose reduce, switch statin, or move to non-statin therapy; stop statin permanently for confirmed immune-mediated necrotising myopathy or rhabdomyolysis; stop colchicine and seek advice if unexplained myopathy or significant renal impairment; refer to lipid specialist for suspected familial hypercholesterolaemia (LDL-C ≥4.9 mmol/L), very high Lp(a), or failure to reach goals.[1][17]

Interactions: colchicine + strong CYP3A4/P-gp inhibitors (e.g. clarithromycin, ciclosporin) — avoid/reduce; statin interactions with CYP3A4 inhibitors and fibrates; aspirin + anticoagulants (bleeding).[17] Reassuringly, no significant interaction between low-dose colchicine and statins/aspirin in trials.[17]

Special populations:

– Pregnancy/lactation: avoid statins while lactating (pregnancy no longer an absolute contraindication per 2026 guidance but generally deferred); bile-acid sequestrants considered safest; avoid PCSK9i, bempedoic acid, icosapent ethyl.[1]

– Renal/hepatic impairment: dose-adjust; heightened colchicine caution; ezetimibe avoided in moderate/severe hepatic impairment.[17][1]

– Frailty/extremes of age: individualise; benefit of BP and lipid lowering persists but weigh harms and goals.[8][41]

 

8. Contraindications and cautions

Absolute contraindications:

– Statins: acute liver failure, decompensated cirrhosis, lactation, severe underlying neuromuscular disease.[1]

– Any agent: prior serious hypersensitivity to that agent.[1]

– Lomitapide/evinacumab: pregnancy (restricted to HoFH; not longevity-clinic agents).[1]

Relative contraindications / specialist input:

– Colchicine with significant renal/hepatic impairment or interacting drugs.[17]

– Aspirin with elevated bleeding risk (peptic ulcer disease, prior GI bleed, concomitant anticoagulants), age ≥60–70 for initiation.[27][51]

– Icosapent ethyl with atrial fibrillation history or bleeding risk.[15]

Harm likely to outweigh benefit with current evidence:

– Routine aspirin for primary prevention in adults ≥60 years, or any age at increased bleeding risk.[27]

– Fish-oil supplements (non-icosapent-ethyl EPA/DHA) for ASCVD prevention — no outcome benefit; STRENGTH/VITAL neutral.[52][53]

– Niacin and CETP inhibitors added to statins — no meaningful benefit.[11][13]

– Senolytics/senomorphics outside trials — unproven benefit, uncharacterised long-term safety in cardiovascular patients.[7]

 

9. Practical management scenarios (CKS-style)

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors

– Recommendation: Offer risk-stratified lipid lowering, BP control, and lifestyle. Strong recommendation.[9][29][20]

– Assessment: QRISK3/PREVENT; lipid profile with apoB, non-HDL-C, Lp(a); HbA1c; BP; CAC if intermediate-risk and decision uncertain.[1][35][39]

– Shared decision-making: discuss absolute benefit, lifetime-exposure rationale, statin diabetes/myalgia risk, and monitoring; document consent.[1]

– Initiation: Mediterranean diet + activity; moderate- or high-intensity statin per risk; add ezetimibe, then PCSK9 mAb to reach LDL-C/apoB goals; treat SBP toward <130 mmHg (consider <120 if high-risk).[1][20]

– Monitoring: lipids/apoB at 8–12 weeks, LFTs, BP; then 6–12 monthly.[1]

– Escalate/refer: LDL-C ≥4.9 mmol/L or FH features → lipid clinic; very high Lp(a) → specialist and trial consideration.[9]

Scenario B — Older, frail patient with multimorbidity

– Recommendation: Consider (individualise), avoiding over-treatment. Conditional recommendation.[8][41]

– Assessment: frailty, cognition, falls, polypharmacy, life expectancy, patient priorities; current BP and lipids.[8][41]

– Shared decision-making: emphasise deprescribing where net benefit is low; align with goals of care.[8]

– Initiation: prioritise BP control (avoid excessive lowering/orthostasis), maintain existing statin if tolerated, moderate intensity often preferred; avoid new aspirin.[27][41]

– Monitoring: closer review of tolerability, renal function, BP, falls.[20]

– Escalate/stop: stop statin if intolerable or limited life expectancy; involve geriatrics/GP.[8]

Scenario C — Patient already under specialist care, adjunctive optimisation

– Recommendation: Offer adjunctive optimisation with informed consent, coordinated with the specialist. Conditional recommendation.[1][6]

– Assessment: confirm on-treatment LDL-C, apoB, Lp(a), hs-CRP, and residual risk; identify gaps (undertreated apoB despite at-goal LDL-C; residual inflammatory risk).[1][6]

– Shared decision-making: agree respective roles; document off-label elements.

– Initiation/adjuncts: intensify to LDL-C <1.4 mmol/L / apoB goal; add icosapent ethyl if TG 1.5–5.6 mmol/L on statin with ASCVD/diabetes; consider colchicine 0.5 mg/day in chronic coronary disease with residual inflammatory risk and adequate renal function (note neutral CLEAR SYNERGY).[15][17][18]

– Monitoring: lipids/apoB, urate (bempedoic acid), renal function (colchicine), AF symptoms (icosapent ethyl).[15][17][1]

– Escalate/stop: recurrent events despite goals → specialist review and Lp(a)-directed trial referral; stop colchicine for intolerance or renal decline.[17][9]

Research-only reminder: senolytics, senomorphics, and specific Lp(a)-lowering agents should be offered only within clinical trials or registries, not as routine adjuncts.[7][34]

 

10. Research gaps and future directions

– Whether specific Lp(a) lowering reduces events (pelacarsen HORIZON, olpasiran OCEAN(a), muvalaplin) — outcome trials pending; currently research-only for outcome benefit.[33][34]

– Inclisiran hard cardiovascular outcomes (ORION-4/VICTORION-2P).[1]

– Optimal role of CCTA/plaque staging and AI-guided therapy intensification in primary prevention (ongoing RCTs); CAC-scoring RCTs have not yet shown event reduction.[40][48][54]

– Colchicine — reconciling positive LoDoCo2/COLCOT with neutral CLEAR SYNERGY (timing, population, dosing).[18]

– GLP-1 RA / SGLT2i for ASCVD prevention in non-diabetic, non-obese longevity populations — limited direct data.[55]

– Senolytics/senomorphics — require rigorous cardiovascular-outcome RCTs in older adults; patient selection, dosing, drug interactions, and long-term safety unknown.[7]

– apoB- and Lp(a)-guided treatment thresholds — cost-effectiveness and outcome data still maturing.[2][38]

Current practice should limit senotherapeutics and Lp(a)-lowering-for-outcome to well-designed trials/registries, while all guideline-backed interventions above form the evidence-based core of longevity ASCVD prevention.

 

References

1. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Blumenthal RS, Morris PB, et al. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423.
2. Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy. Luebbe S, Sniderman AD, Moran AE, Wilkins JT, Kohli-Lynch CN. JAMA. 2026;:2847303. doi:10.1001/jama.2026.2986.
3. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus From the National Lipid Association. Soffer DE, Marston NA, Maki KC, et al. Journal of Clinical Lipidology. 2024 Sep-Oct;18(5):e647-e663. doi:10.1016/j.jacl.2024.08.013.
4. Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar. Preiss D, Tobert JA, Hovingh GK, Reith C. Journal of the American College of Cardiology. 2020;75(16):1945-1955. doi:10.1016/j.jacc.2019.11.072.
5. Systemic Review of Inflammatory Pathways and Immune Modulation in Atherosclerotic Cardiovascular Disease. Wang Q, Sui YX, Zhang LT, Meng N, Chen HY. The American Journal of Cardiology. 2025;:S0002-9149(25)00465-5. doi:10.1016/j.amjcard.2025.08.013.
6. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. Circulation. 2025;152(23):e443-e466. doi:10.1161/CIR.0000000000001394.
7. Pharmacological Targeting of the Senescence-Associated Secretory Phenotype in Atherosclerosis: Therapeutic Potential of Senolytics and Senomorphics. Manni E, Al-Kuraishy HM, Fawzy MN, Batiha GE. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2026;:10.1007/s00210-026-05416-4. doi:10.1007/s00210-026-05416-4.
8. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
9. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Blumenthal RS, Morris PB, Gaudino M, et al. Journal of the American College of Cardiology. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016.
10. PCSK9 Inhibitors and Ezetimibe With or Without Statin Therapy for Cardiovascular Risk Reduction: A Systematic Review and Network Meta-Analysis. Khan SU, Yedlapati SH, Lone AN, et al. BMJ (Clinical Research Ed.). 2022;377:e069116. doi:10.1136/bmj-2021-069116.
11. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF, Polonsky TS, Miedema MD, et al. Circulation. 2019;139(25):e1144-e1161. doi:10.1161/CIR.0000000000000626.
12. Proprotein Convertase Subtilisn/Kexin Type 9 Inhibitors and Small Interfering RNA Therapy for Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis. Imran TF, Khan AA, Has P, et al. PloS One. 2023;18(12):e0295359. doi:10.1371/journal.pone.0295359.
13. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF, Polonsky TS, Miedema MD, et al. Journal of the American College of Cardiology. 2019;73(24):3210-3227. doi:10.1016/j.jacc.2018.11.004.
14. FDA Orange Book. FDA Orange Book.
15. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. Bhatt DL, Steg PG, Miller M, et al. The New England Journal of Medicine. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792.
16. Profound Reductions in First and Total Cardiovascular Events With Icosapent Ethyl in the REDUCE-IT Trial: Why These Results Usher in a New Era in Dyslipidaemia Therapeutics. Boden WE, Bhatt DL, Toth PP, et al. European Heart Journal. 2020;41(24):2304-2312. doi:10.1093/eurheartj/ehz778.
17. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week. Nelson K, Fuster V, Ridker PM. Journal of the American College of Cardiology. 2023;82(7):648-660. doi:10.1016/j.jacc.2023.05.055.
18. Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT. Jannink J, van Zelm AM, Chemlal S, et al. Current Atherosclerosis Reports. 2026;28(1):11. doi:10.1007/s11883-025-01382-z.
19. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Virani SS, Newby LK, Arnold SV, et al. Journal of the American College of Cardiology. 2023;82(9):833-955. doi:10.1016/j.jacc.2023.04.003.
20. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Jones DW, Ferdinand KC, Taler SJ, et al. Journal of the American College of Cardiology. 2025;86(18):1567-1678. doi:10.1016/j.jacc.2025.05.007.
21. Intensive Blood Pressure Treatment Goals: Evidence for Cardiovascular Protection From Observational Studies and Clinical Trials. Whelton PK, Bundy JD, Carey RM. American Journal of Hypertension. 2022;35(11):905-914. doi:10.1093/ajh/hpac045.
22. Lowering Systolic Blood Pressure to Less Than 120 Mm Hg Versus Less Than 140 Mm Hg in Patients With High Cardiovascular Risk With and Without Diabetes or Previous Stroke: An Open-Label, Blinded-Outcome, Randomised Trial. Liu J, Li Y, Ge J, et al. Lancet (London, England). 2024;404(10449):245-255. doi:10.1016/S0140-6736(24)01028-6.
23. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis. Bundy JD, Li C, Stuchlik P, et al. JAMA Cardiology. 2017;2(7):775-781. doi:10.1001/jamacardio.2017.1421.
24. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care. 2026;49(Suppl 1):S216-S245. doi:10.2337/dc26-S010.
25. Diagnosis and Treatment of Type 2 Diabetes in Adults. Kalyani RR, Neumiller JJ, Maruthur NM, Wexler DJ. JAMA. 2025;334(11):984-1002. doi:10.1001/jama.2025.5956.
26. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Neuen BL, Fletcher RA, Heath L, et al. Circulation. 2024;150(22):1781-1790. doi:10.1161/CIRCULATIONAHA.124.071689.
27. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. JAMA. 2022;327(16):1577-1584. doi:10.1001/jama.2022.4983.
28. Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. Kumbhani DJ, Gibson CM, Kinlay S, et al. Journal of the American College of Cardiology. 2026;:S0735-1097(26)06704-5. doi:10.1016/j.jacc.2026.05.037.
29. Effectiveness of Mediterranean Diet for the Primary Prevention of Cardiovascular Diseases: A Systematic Review and Meta-Analysis Featured in the Italian National Guidelines “La Dieta Mediterranea”. Volpe R, Ciccone MM, Pala B, et al. Nutrition (Burbank, Los Angeles County, Calif.). 2026;148:113038. doi:10.1016/j.nut.2025.113038.
30. Comparison of Seven Popular Structured Dietary Programmes and Risk of Mortality and Major Cardiovascular Events in Patients at Increased Cardiovascular Risk: Systematic Review and Network Meta-Analysis. Karam G, Agarwal A, Sadeghirad B, et al. BMJ (Clinical Research Ed.). 2023;380:e072003. doi:10.1136/bmj-2022-072003.
31. The Mediterranean Diet and Cardiovascular Health. Martínez-González MA, Gea A, Ruiz-Canela M. Circulation Research. 2019;124(5):779-798. doi:10.1161/CIRCRESAHA.118.313348.
32. Medical Nutrition Therapy (MNT) Evidence Update: Comparative Effectiveness of Dietary Programs for Reducing Mortality and Cardiovascular Events in Adults With Increased Cardiovascular Disease Risk. Esmaeilinezhad Z, Torbahn G, Johnston BC. Advances in Nutrition (Bethesda, Md.). 2025;16(4):100399. doi:10.1016/j.advnut.2025.100399.
33. Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies. Alhomoud IS, Talasaz A, Mehta A, et al. Pharmacotherapy. 2023;43(10):1051-1063. doi:10.1002/phar.2851.
34. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(1):e48-e60. doi:10.1161/ATV.0000000000000147.
35. 2026 Dyslipidemia Guideline-at-a-Glance. Wiggins BS, Barac A, Benziger CP, et al. Journal of the American College of Cardiology. 2026;87(19):2617-2623. doi:10.1016/j.jacc.2026.02.4872.
36. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. Michos ED, McEvoy JW, Blumenthal RS. The New England Journal of Medicine. 2019;381(16):1557-1567. doi:10.1056/NEJMra1806939.
37. Lipoprotein(a). Mora S, Kronenberg F. JAMA. 2025;333(21):1918-1919. doi:10.1001/jama.2025.2373.
38. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men. Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Journal of the American College of Cardiology. 2024;83(23):2262-2273. doi:10.1016/j.jacc.2024.03.423.
39. Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. Khan SS, Bhave N, Blumenthal RS, et al. Circulation. 2026;154(4):e159-e180. doi:10.1161/CIR.0000000000001447.
40. Coronary Computed Tomography Angiography in Prediction of First Coronary Events. Bergström G, Engström G, Björnson E, et al. JAMA. 2026;335(3):245-254. doi:10.1001/jama.2025.21077.
41. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Qaseem A, Wilt TJ, Rich R, et al. Annals of Internal Medicine. 2017;166(6):430-437. doi:10.7326/M16-1785.
42. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA. JAMA. 2022;327(16):1585-1597. doi:10.1001/jama.2022.3337.
43. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Arnett DK, Blumenthal RS, Albert MA, et al. Journal of the American College of Cardiology. 2019;74(10):e177-e232. doi:10.1016/j.jacc.2019.03.010.
44. Risk Scoring for the Primary Prevention of Cardiovascular Disease. Hernandez AV, Diaz-Arocutipa C, Valenzuela G, et al. The Cochrane Database of Systematic Reviews. 2026;2:CD016333. doi:10.1002/14651858.CD016333.
45. Use of Risk Assessment Tools To Guide Decision-Making in The Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Journal of the American College of Cardiology. 2019;73(24):3153-3167. doi:10.1016/j.jacc.2018.11.005.
46. Comparison of American and European Guidelines for Primary Prevention of Cardiovascular Disease: JACC Guideline Comparison. Fegers-Wustrow I, Gianos E, Halle M, Yang E. Journal of the American College of Cardiology. 2022;79(13):1304-1313. doi:10.1016/j.jacc.2022.02.001.
47. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations. Anderson TS, Wilson LM, Sussman JB. JAMA Internal Medicine. 2024;184(8):963-970. doi:10.1001/jamainternmed.2024.1302.
48. The Lancet Commission on Rethinking Coronary Artery Disease: Moving From Ischaemia to Atheroma. Zaman S, Wasfy JH, Kapil V, et al. Lancet (London, England). 2025;405(10486):1264-1312. doi:10.1016/S0140-6736(25)00055-8.
49. A Pesco-Mediterranean Diet With Intermittent Fasting: JACC Review Topic of the Week. O’Keefe JH, Torres-Acosta N, O’Keefe EL, et al. Journal of the American College of Cardiology. 2020;76(12):1484-1493. doi:10.1016/j.jacc.2020.07.049.
50. Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Patnode CD, Redmond N, Iacocca MO, Henninger M. JAMA. 2022;328(4):375-388. doi:10.1001/jama.2022.7408.
51. Aspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in Women. Shufelt CL, Mora S, Manson JE. JAMA. 2022;328(7):672-673. doi:10.1001/jama.2022.11951.
52. Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids: JACC Focus Seminar. Weinberg RL, Brook RD, Rubenfire M, Eagle KA. Journal of the American College of Cardiology. 2021;77(5):593-608. doi:10.1016/j.jacc.2020.11.060.
53. Omega-3 Fatty Acid Therapy for Cardiovascular Disease: Justified or Not?. Maki KC, Dicklin MR. Current Opinion in Cardiology. 2020;35(4):417-422. doi:10.1097/HCO.0000000000000741.
54. Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop. Greenland P, Michos ED, Redmond N, et al. JACC. Cardiovascular Imaging. 2021;14(7):1454-1465. doi:10.1016/j.jcmg.2020.06.042.
55. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Ndumele CE, Neeland IJ, Tuttle KR, et al. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001186.